#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myelodysplastic syndrome B precursor type acute leukaemia Hereditary angioedema with C1 esterase inhibitor deficiency Anti-myelin-associated glycoprotein antibodies positive Penile squamous cell carcinoma Hypochondroplasia Phaeochromocytoma Alexander disease Chronic graft versus host disease in intestine Macular telangiectasia Oropharyngeal squamous cell carcinoma Fragile X syndrome Chronic graft versus host disease in skin Dermatitis Warm autoimmune haemolytic anaemia More trials…

    Learn about Rare Diseases

    Fabry’s disease Breast angiosarcoma Fragile X syndrome – Basic Information Lymphangioma – Trials in Disease Erdheim-Chester disease – Treatment Mucopolysaccharidosis II – Treatment Osteosarcoma recurrent – Diagnostics Mast cell activation syndrome – Diagnostics Waldenstrom’s macroglobulinaemia recurrent Haemophilia A without inhibitors – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Taldefgrobep Alfa Darovasertib Heterodimeric Interleukin-15 Giroctocogene Fitelparvovec LUMC-BOB1-B7-TCR.1 Ag-946 Stro-002 Emapalumab Streptococcus Pneumoniae Macrogol 3350 RNMB3 SIGVOTATUG VEDOTIN Ivonescimab Ambrosia Artemisiifolia (302) Aup1602-C Anb032 Sodium Sulfate Anhydrous Clofutriben SODIUM DIHYDROGEN PHOSPHATE Nemolizumab More therapies…

    Learn about Your Condition

    Oedema Thymoma Von Willebrand's disease Proteinuria Immunodeficiency Hypoxia Thrombotic microangiopathy Primary hyperaldosteronism Vulvovaginal pain Staphylococcal bacteraemia Cushing's syndrome Osteosarcoma recurrent Gastrooesophageal cancer Microscopic polyangiitis Malformation venous More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nutritional and Metabolic Diseases

  • Study on the Safety and Effectiveness of GSK4532990 for Adults Aged 18-65 with Alcohol-Related Liver Disease

    Recruiting

    2 1
    Investigated Diseases:
    • Alcoholic liver disease
    Denmark France Germany Greece Italy Poland +2

  • Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

    Recruiting

    3 1 1
    Investigated Diseases:
    • Obesity
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Austria Belgium Bulgaria Czechia France Greece +8

  • Study comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity

    Recruiting

    3 1
    Investigated Diseases:
    • Obesity
    • Overweight
    Investigated Drugs:
    • Cagrilintide
    Greece Hungary Portugal Sweden

  • Study of PF-08653945 Bioavailability After Subcutaneous Injection in the Thigh, Upper Arm, or Abdomen in Adults with Obesity

    Recruiting

    1 1 1
    Investigated Diseases:
    • Overweight
    Belgium

  • A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated steatohepatitis
    Austria Belgium Bulgaria France Germany Greece +4

  • Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated steatohepatitis
    Austria Belgium Bulgaria France Germany Greece +4
Previous Page
1 … 21 22 23 24 25 … 61
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!